RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A randomized phase III joint study of the AIO, ARO and DGAV

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516271-32-00

Acronym

RACE

Enrollment

342

Registered

2024-11-12

Start date

2020-06-03

Completion date

Unknown

Last updated

2024-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of the gastroesophageal junction (AEG type I-III)

Brief summary

Progression-free survival (PFS)

Detailed description

Overall survival, including survival rates after 1, 3 and 5 years, R0 resection rate, Number of harvested lymph nodes, Site of tumor relapse, Perioperative morbidity and mortality rate, Safety and toxicity as assessed by NCI CTC criteria, Quality of life by using the EORTC QLQ-C30 and the esophagogastric module OG25

Interventions

DRUGFLUOROURACIL

DRUGDOCETAXEL

DRUGOXALIPLATIN

DRUGCALCIUM FOLINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS)	—

Secondary

Measure	Time frame
Overall survival, including survival rates after 1, 3 and 5 years, R0 resection rate, Number of harvested lymph nodes, Site of tumor relapse, Perioperative morbidity and mortality rate, Safety and toxicity as assessed by NCI CTC criteria, Quality of life by using the EORTC QLQ-C30 and the esophagogastric module OG25	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026